Enterprise Value

2.022B

Cash

552M

Avg Qtr Burn

-114.7M

Short % of Float

5.42%

Insider Ownership

4.67%

Institutional Own.

98.58%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DTX401 Details
Glycogen Storage Disease Type Ia

Phase 3

Data readout

DTX301 Details
Ornithine transcarbmylase deficiency

Phase 3

Update

Setrusumab (UGX143) Details
Osteogenesis imperfecta

Phase 2/3

Data readout

UX701 Details
Rare diseases, Wilson's disease

Phase 1/2

Data readout

UX053 Details
Rare diseases, glycogen storage disease type III

Phase 1/2

Data readout

GTX-102 Details
Angelman Syndrome

Phase 1/2

Interim update